"What" Series

What is Targeted Therapy?

3 April 2024
2 min read

Targeted therapy is a type of cancer treatment that uses drugs or other substances to specifically attack cancer cells without harming normal cells as much as possible. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, targeted therapy is designed to interact with specific molecular targets that are associated with the growth, progression, and spread of cancer.

Key aspects of targeted therapy include:

·Molecular Targets: These are proteins or other molecules on or inside cancer cells that play a critical role in the cancer's development and survival. Examples include growth factor receptors, enzymes, and proteins that control cell division.

·Drug Design: Targeted therapies are engineered to bind to these specific targets, inhibiting their function and thereby slowing or stopping cancer growth. These drugs can be monoclonal antibodies, small molecule inhibitors, or other types of molecules.

·Personalized Medicine: Targeted therapies are often used in the context of personalized or precision medicine, where treatment decisions are based on the genetic makeup of a patient's tumor.

Selectivity: The goal of targeted therapy is to selectively inhibit cancer cell growth while sparing healthy cells, which can reduce side effects compared to traditional chemotherapy.

·Resistance: Cancer cells can sometimes develop resistance to targeted therapies, which may involve changes in the target itself or alternative pathways that allow the cancer to continue growing.

·Combination Therapies: To overcome resistance and enhance efficacy, targeted therapies are sometimes used in combination with other treatments, such as chemotherapy, radiation, or immunotherapy.

·Clinical Development: Targeted therapies undergo rigorous clinical trials to demonstrate their safety and effectiveness in treating specific types of cancer.

Targeted therapy has revolutionized cancer treatment by offering more precise and often less toxic options for patients. It is an evolving field, with ongoing research aimed at identifying new targets and developing more effective therapies for a broader range of cancers.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

REGENXBIO Study in The Lancet: Single-Dose Gene Therapy ABBV-RGX-314 for Wet AMD
Latest Hotspot
3 min read
REGENXBIO Study in The Lancet: Single-Dose Gene Therapy ABBV-RGX-314 for Wet AMD
3 April 2024
REGENXBIO Reveals Study in The Lancet on Initial Trial for Single-Dose Gene Therapy ABBV-RGX-314 Targeting Wet Age-Related Macular Degeneration.
Read →
Neurocrine Initiates Phase I Trial of VMAT2 Inhibitor NBI-1065890
Latest Hotspot
2 min read
Neurocrine Initiates Phase I Trial of VMAT2 Inhibitor NBI-1065890
2 April 2024
Neurocrine Biosciences Launches Early-Stage Trial for New VMAT2 Blocker, NBI-1065890, in Adult Participants.
Read →
Relaxin Receptors: Therapeutic Opportunity for Heart Failure and Pulmonary Arterial Hypertension
Hot Spotlight
5 min read
Relaxin Receptors: Therapeutic Opportunity for Heart Failure and Pulmonary Arterial Hypertension
2 April 2024
Advancing GPCR-Targeted Therapy: Tectonic Therapeutics' GEODe Platform Overcomes Discovery Challenges.
Read →
Gilead-Xilio Ink Deal on IL-12 Oncology Project
Latest Hotspot
3 min read
Gilead-Xilio Ink Deal on IL-12 Oncology Project
2 April 2024
Gilead and Xilio have entered into a unique licensing deal dedicated to the development of an oncology-targeted IL-12 initiative.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.